Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial
- 27 September 2023
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 24 (2) , 150-160
Abstract
No abstract availableKeywords
Funding Information
- Johns Hopkins University
- Johns Hopkins University Bloomberg School of Public Health (75N93019D00031)
- National Institutes of Health
- Division of Intramural Research (HHSN272200900010C)
This publication has 29 references indexed in Scilit:
- Dengue infectionNature Reviews Disease Primers, 2016
- The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge modelScience Translational Medicine, 2016
- Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?Expert Review of Vaccines, 2015
- Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic DiseaseNew England Journal of Medicine, 2015
- Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive AdultsThe Journal of Infectious Diseases, 2015
- The global distribution and burden of dengueNature, 2013
- A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes inFlavivirus‐Naive AdultsThe Journal of Infectious Diseases, 2010
- ORIGIN OF DENGUE TYPE 3 VIRUSES ASSOCIATED WITH THE DENGUE OUTBREAK IN DHAKA, BANGLADESH, IN 2000 AND 2001The American Journal of Tropical Medicine and Hygiene, 2006
- First Outbreak of Dengue Hemorrhagic Fever, BangladeshEmerging Infectious Diseases, 2002
- Recovery of Dengue Viruses from Patients during Epidemics in Puerto Rico and East PakistanThe American Journal of Tropical Medicine and Hygiene, 1966